Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention

H. Alexander, John; Wojdyla, Daniel; N. Vora, Amit; Thomas, Laine; B. Granger, Christopher; G. Goodman, Shaun; Aronson, Ronald; Windecker, Stephan; Mehran, Roxana; D. Lópes, Renato

doi:10.1161/circulationaha.120.046534

Public

Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention

Published in Circulation • Mar 29, 2020

Authors:

John H. Alexander

Daniel Wojdyla

Amit N. Vora

Abstract

BACKGROUND: In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients wi...

Subject

Medicine

Apixaban

Aspirin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!